Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials

Author： Penel Nicolas  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 653-661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials

By Penel Nicolas   Leblond Pierre   Lansiaux Amélie   Clisant Stéphanie   Dansin Eric   Adenis Antoine   Bonneterre Jacques  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 839-843

Springer Publishing Company

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng  

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Proposal for size justification of expanded cohort at phase-2-recommended dose

By Penel Nicolas  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 713-715

Springer Publishing Company

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

By  

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

By Sargent Daniel  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 556-562

Taylor & Francis Ltd

Access to resources Recommend Favorite